Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026

About this update from Bavarian Nordic A/s

[{"type":"image","alt":"Bavarian Nordic A/S","displaySize":"","headline":null,"caption":"Bavarian Nordic A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":224,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/8b66f55ff95ddf48491741d682cbdfa0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X7d037B4FI93H1mEWMcPsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8b66f55ff95ddf48491741d682cbdfa0","width":224,"height":118}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public Preparedness.","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"2026 guidance reflects continued growth in Travel Health (10% from own products, 14% at constant exchange rates) and a normalized year in Public Preparedness, both in line with the communicated mid-term growth ambitions.","length":220,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":365,"olType":false},{"type":"text","content":"COPENHAGEN, Denmark, February 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial results for 2025 and provided its financial guidance for 2026.","length":184,"tagName":"p"},{"type":"text","content":"Revenue in 2025 was DKK 6,244 million, compared to the latest guidance of approximately DKK 6,000 million, and included the following:","length":134,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"DKK 3,105 million from Public Preparedness, exceeding the normal annual base business by more than DKK 1,000 million as the surge in demand for mpox vaccines continued during 2025.","length":180,"tagName":"p"}]},{"val":[{"type":"text","content":"DKK 2,963 million from Travel Health, exceeding the latest guidance by nearly DKK 200 million and demonstrating an increase of 30% over 2024. Strong demand for rabies and TBE vaccines continued with 34% and 20% growth respectively, while the first-year of sales for the chikungunya vaccine reached DKK 85 million, exceeding the latest guidance by DKK 10 million. Revenue from the sale of partnered products, which will discontinue from 2026, totaled DKK 228 million.","length":466,"tagName":"p"}]},{"val":[{"type":"text","content":"DKK 176 millio...

More updates from Bavarian Nordic A/s